US · ACRS
Aclaris Therapeutics, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Wayne, PA 19087
- Website
- aclaristx.com
Price · as of 2025-12-31
$4.41
Market cap 310.95M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $27.51 | +523.81% |
| Intrinsic Value(DCF) | $1.33 | -69.84% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $25.16 | +470.54% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $16.84 | ||||
| 2016 | $31.14 | ||||
| 2017 | $21.28 | ||||
| 2018 | $5.77 | $53.28 | $1.10 | $0.00 | $0.00 |
| 2019 | $1.11 | $23.77 | $0.00 | $0.00 | $185.62 |
| 2020 | $25.21 | $41.81 | $0.01 | $0.00 | $0.00 |
| 2021 | $15.81 | $26.16 | $1.68 | $0.00 | $0.00 |
| 2022 | $7.89 | $50.38 | $6,207.16 | $0.00 | $0.00 |
| 2023 | $1.41 | $21.93 | $2.46 | $0.00 | $0.00 |
| 2024 | $1.83 | $27.19 | $0.00 | $0.00 | $51.48 |
| 2025 | $3.05 | $27.51 | $0.22 | $0.00 | $25.16 |
AI valuation
Our deep-learning model estimates Aclaris Therapeutics, Inc.'s (ACRS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $27.51
- Current price
- $4.41
- AI upside
- +523.81%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.33
-69.84% upside
Graham-Dodd
—
— upside
Graham Formula
$25.16
+470.54% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ACRS | Aclaris Therapeutics, Inc… | $4.41 | 310.95M | +524% | -70% | — | +471% | -5.76 | 3.63 | 47.81 | -3.46 | — | 3.63 | 73.28% | -975.91% | -829.58% | -50.20% | 2416.55% | -34.10% | 0.00 | — | 5.28 | 5.28 | 0.31 | -6901.00% | -5819.00% | 13383.00% | -12.62% | -1.64 | 1494.19% | 0.00% | 0.00% | 0.00% | -2.92 | -4.72 | 28.46 | -5.14 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| BIOA | BioAge Labs, Inc. | $22.27 | 798.49M | — | — | — | — | -0.69 | 0.15 | — | 4.33 | — | 0.15 | 0.00% | — | — | -94.98% | 95.18% | -37.02% | 0.03 | -33.04 | 12.86 | 12.76 | 5.04 | -2246.00% | — | 3826.00% | -106.31% | -1.85 | 63.16% | 0.00% | 0.00% | 772.94% | 3.80 | 5.72 | — | 0.23 |
| CABA | Cabaletta Bio, Inc. | $3.32 | 319.6M | — | — | — | — | -0.79 | 0.60 | — | 0.51 | -1.89 | 0.60 | 0.00% | — | — | -59.64% | -6352.34% | -52.82% | 0.10 | -167.30 | 6.15 | 6.05 | 1.35 | 4182.00% | — | 6674.00% | -98.71% | -3.26 | -4590.51% | 0.00% | 0.00% | 0.00% | 0.45 | 0.63 | — | -2.29 |
| EDIT | Editas Medicine, Inc. | $2.20 | 214.76M | +883% | +13% | — | +6,172% | -0.60 | 1.05 | 4.38 | 0.40 | -1.40 | 1.05 | 100.00% | -777.22% | -733.72% | -98.10% | 1925.86% | -56.40% | 0.26 | — | 3.75 | 3.71 | 0.41 | 4257.00% | -5864.00% | 6005.00% | -154.71% | -2.72 | 1680.16% | 0.00% | 0.00% | 15.11% | 0.37 | 0.43 | -2.89 | -7.20 |
| MASS | 908 Devices Inc. | $6.90 | 249.73M | +193% | -84% | — | — | -1.30 | 0.82 | 1.58 | -0.71 | -1.49 | 1.36 | 50.18% | -128.65% | -121.09% | -51.56% | -197.59% | -39.84% | 0.06 | — | 4.10 | 3.27 | 0.85 | 8761.00% | 1872.00% | 1382.00% | -32.80% | -1.20 | -79.76% | 0.00% | 0.00% | 0.00% | -0.40 | -1.01 | 0.52 | -1.50 |
| MDXH | MDxHealth S.A. | $3.40 | 174.64M | +722% | +1,396% | — | — | -2.93 | 4.89 | 0.81 | -3.90 | — | -1.18 | 61.23% | -27.45% | -42.28% | -224.25% | -91.23% | -17.26% | 4.05 | -3.24 | 1.57 | 1.44 | -0.60 | -3012.00% | 2829.00% | -2198.00% | -28.53% | -0.43 | -76.34% | 0.00% | 0.00% | 7.75% | -3.47 | -4.15 | 0.95 | -2.74 |
| NEO | NeoGenomics, Inc. | $9.83 | 255.21M | +138% | -61% | — | — | -2.25 | 0.29 | 0.33 | 318.65 | -6.35 | 9.47 | 38.85% | -9.09% | -14.85% | -12.42% | -5.70% | -7.21% | 0.56 | -17.61 | 4.26 | 3.61 | 179.17 | 3548.00% | 1011.00% | -3602.00% | -8.95% | 0.06 | -1.92% | 0.00% | 0.00% | 0.00% | -8.41 | -25.53 | 0.76 | 0.46 |
| OMI | Owens & Minor, Inc. | $2.68 | 207.07M | +942% | +49% | — | — | -2.12 | 1.36 | 0.07 | 48.40 | -0.28 | -0.72 | 20.74% | -1.94% | -3.39% | -48.70% | -7.35% | -7.44% | 3.79 | -1.44 | 1.08 | 0.39 | 35.40 | 76000.00% | 355.00% | -11251.00% | -8.69% | 0.09 | -2.36% | 0.00% | 0.00% | 0.00% | -13.75 | -42.87 | 0.27 | 2.30 |
| SENS | Senseonics Holdings, Inc. | $8.27 | 337.9M | +200% | +728% | — | — | -5.18 | -24.61 | 18.13 | -5.73 | -38.01 | -23.91 | 2.37% | -333.05% | -349.84% | -817.17% | 267.39% | -65.88% | -3.69 | -8.87 | 2.35 | 2.13 | 0.20 | 1364.00% | 37.00% | -1107.00% | -15.39% | -1.56 | 224.02% | 0.00% | 0.00% | 0.00% | -5.26 | -6.28 | 17.53 | -12.73 |
| XGN | Exagen Inc. | $3.62 | 82.04M | +641% | +1,119% | — | — | -3.89 | 6.16 | 1.06 | -5.36 | — | 6.16 | 59.51% | -24.51% | -27.17% | -93.78% | -136.76% | -29.74% | 2.41 | -6.10 | 2.70 | 2.21 | -0.09 | -3806.00% | 589.00% | -978.00% | -23.46% | -0.98 | -138.35% | 0.00% | 0.00% | 0.00% | -4.38 | -4.33 | 1.07 | -7.36 |
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
- CEO
- Neal S. Walker
- Employees
- 61
- Beta
- 0.86
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.33 ÷ $4.41) − 1 = -69.84% (DCF, example).